|
Spain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
The Spain Pharmaceuticals and Healthcare Report
Independent 5-year pharmaceutical and healthcare industry forecasts for Spain .
Original pharmaceutical and healthcare market research and pharmaceutical and healthcare sector trend analysis for the Spanish pharmaceutical and healthcare industry.
Competitive intelligence, Spanish pharmaceutical and healthcare company rankings and SWOT analyses on international and domestic pharmaceutical and healthcare companies in the Spanish market.
The Spain Pharmaceuticals and Healthcare Report has been researched at source and features the latest available data and forecasts to end- covering drugs and healthcare expenditure, the prescription, OTC and generics markets, and foreign trade; company rankings and competitive landscapes including multinational and national drugs companies; and analysis of latest industry news, trends and regulatory developments.
Business Monitor International’s Spain Pharmaceuticals and Healthcare Report provides industry professionals, market investors and corporate and financial services analysts with independent forecasts and competitive intelligence on the Spanish pharmaceutical and healthcare industry.
Key Benefits of Report
- Benchmark BMI’s Independent 5-year Pharmaceutical and Healthcare Industry Forecasts on Spain to test other views – a key input for successful budgeting and strategic business planning in the Spanish pharmaceutical and healthcare market.
- Target Business Opportunities & Risks in the Spanish Pharmaceutical and Healthcare Sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Spain .
- Exploit The Latest Competitive Spanish Pharmaceutical and Healthcare Intelligence & company SWOTS on your competitors and peers through company rankings by sales, market share and ownership structure – includes multi-national and national companies in Spain .
Coverage
Executive Summary & Industry SWOT
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI’s forecast analysis, and taken together with BMI’s Economic and Business Environment SWOTS, give a complete overview of market climate.
Market Summary
Outline of market characteristics, growth factors, leading therapeutic segments and a competitivness of the market.
Regulatory Regime
Guide to and analysis of country intellectual property developments and pricing & reimbursement issues, which constitute the regulatory make-up of the market.
Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D and patent legislation.
BMI 5-Year Industry Forecast
5-Year Forecasts to end- for all key industry indicators (see list below), supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
- Drug market expenditure (US$bn); drug expenditure per capita (US$); as % of gdp
- Prescription drug market (US$bn)/as % of total market; sales by alimentary tract/metabolism; antibiotics, cardiovascular, central nervous system, oncology, musculoskeletal and respiratory system
- OTC market (US$bn)/as % of total market (sales by analgesic, cough and cold, digestives, skin treatments, vitamins and minerals)
- Generics market (US$bn)/ as % of total market
- Health expenditure (US$bn, % of gdp and per capita); public sector health expenditure as % of total; number of hospitals; beds, hospital admissions, doctors, births and deaths per 000 population
Forecasts based on bespoke BMI economic modelling, using historical data sets of macroeconomic and industry variables to derive rigorous statistical relationships, anchored in advanced linear regression techniques.
BMI 5-Year Macroeconomic Forecasts
BMI forecasts for all headline macroeconomic indicators, including:
Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt
Competitive Landscape & Profiles
Intelligence on the market position of major MNC power houses and indigenous companies. BMI profiles key research-based companies. Company SWOTS are provided for all key strategic players, complete with a company activity overview, its leading products and analysis of business opportunities.
|
Spain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Chapter - Executive Summary |
| Swot Analysis |
| Spain: Pharmaceutical And Healthcare Industry SWOT |
| Spain Political SWOT |
| Spain Economic SWOT |
Chapter - Pharmaceutical Business Environment Ratings |
| Table: Western Europe Pharmaceutical Business Environment Rankings |
| Limits To Potential Returns |
| Risks to Realisation of Potential Returns |
Chapter - Spain – Market Summary |
| Regulatory Regime |
| Intellectual Property Issues |
| Pricing and Reimbursement Issues |
| Table: Timeline – Spain's Pharmaceutical Pricing Reforms |
| Price Cut On Older Drugs |
| Reference Pricing System |
| Industry Reaction |
| Parallel Trade |
Chapter - Industry Developments |
| Table: SNS Debt 2007 |
Chapter - Industry Forecast Scenario |
| Overall Market Forecast |
| Table: Spain's Drug Market Indicators, 2004-2013 |
| Key Growth Factors – Industry |
| Table: Spain's Health Expenditure Indicators, 2004-2013 |
| Key Growth Factors – Macroeconomic |
| Table: Spain - Economic Activity |
| Prescription Market Forecast |
| Table: Spain – Prescription Drug Market Forecast (2004-2013) |
| Patented Market Forecast |
| Table: Spain's Patented Drugs Market Indicators, 2004-2013 |
| Generics Market Forecast |
| Table: Spain's Generics Market Indicators, 2004-2013 |
| OTC Market Forecast |
| Table: Spain's OTC Market Forecast Indicators (US$mn unless otherwise stated) |
| Export/Import Forecast |
| Table: Pharmaceutical Trade Indicators, 2004-2013 (US$mn) |
| Medical Devices Forecast |
| Table: Spain's Medical Device Market, 2002-2012 (US$bn unless otherwise stated) |
| Key Risks to BMI Forecasts |
Chapter - Competitive Landscape |
| Manufacturers |
| Foreign Sector |
| Indigenous Sector |
| Generics Sector |
| Research/Biotechnology Sector Developments |
| Table: Firms Active In Nanofarma Consortium |
| Government Investment |
Chapter - Company Profiles |
| Leading Multinational Manufacturers |
| GlaxoSmithKline (GSK) |
| Pfizer |
| Novartis |
| Sanofi-Aventis |
| Merck & Co |
| Indigenous Manufacturers |
| Almirall Prodesfarma |
| Dr Esteve |
Chapter - Country Snapshot: Spain Demographic Data |
| Section 1: Population |
| Table: Demographic Indicators, 2005-2030 |
| Table: Rural/Urban Breakdown, 2005-2030 |
| Section 2: Education and Healthcare |
| Table: Education, 2002-2005 |
| Table: Vital Statistics, 2005-2030 |
| Section 3: Labour Market and Spending Power |
| Table: Employment Indicators, 2001-2006 |
| Table: Consumer Expenditure, 2000-2012 (US$) |
| Table: Average Annual Manufacturing Wages, 2000-2012 |
Chapter - BMI Forecast Modelling |
| How We Generate Our Pharmaceutical Industry Forecasts |
| Pharmaceutical Business Environment Ratings Methodology |
| Ratings Overview |
| Table: Pharmaceutical Business Environment Indicators |
| Weighting |
| Table: Weighting Of Components |
| Sources |
|
Spain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
BMI calculates Spain’s pharmaceutical expenditure to have been EUR15.25bn (US$21.79bn) in 2008. By 2013, we expect the total amount spent on prescription and OTC medicines to have reached a value of EUR19.00bn (US$24.05bn) equating to a compound annual growth rate of 4.5% in local currency terms. In BMI’s Business Environment Rankings for 2009, Spain is ranked 4th out of the 9 Western European markets surveyed. Globally, France is ranked in 7th position just behind Belgium and Puerto Rico, after moving up two places in Q209.
In January 2009, several of Spain's regional autonomies called for an overhaul of the pharmaceutical and healthcare co-payment system, with the goal to rein in bulging healthcare expenditure and reduce existing levels of debt. Suggestions included making pensioners contribute towards drug co-payments. The ministry of health dismissed the opportunity to debate the issue, however, stating that savings would not offset the social cost of such changes.
In February 2009, the Spanish Ministry of Health announced that it is to launch campaigns to educate and encourage citizens to purchase non-prescription drugs for disorders that can be self-treated. The aim of the project is to reduce the burden on physicians and the government's health budget, so healthcare resources can be used to treat patients with more serious illnesses, patients can be provided with up-to-date medication that may cost more and a larger number of serious disorders can be treated.
Thirteen new groups of medicines were added to the reference price scheme which came into force in March 2009. A third of prescription-only medicines dispensed in Spain are subject to the reference pricing system, and the average decrease of the price of medicines under the scheme has reached 40%. Therefore, in two years, the price of these medicines has nearly halved.
BMI believes that the recent price cuts will be welcomed by consumers - as well as leading to healthcare savings, the scheme highlights the presence of regulation in the market and inhibits pharmaceutical companies from completely controlling prices. However, in previous years the industry has criticised this policy, as profit margins have been continually squeezed. It will therefore not come as a surprise if the government's latest cost-containment measures are similarly received by drug producers.
In March 2009, Spain’s National Pharmacists’ Association, said that the country required a better generic medicine’s policy and that measures that constantly lowered the price of medicines were eroding the role of generic medicines. The new pricing order that was introduced in the same month revealed that out of the 5,289 presentations that are subject to reference pricing, 2,847 were generic medicines. The Association said that this presents little incentive to drug makers to continue to produce existing generic medicines, or to register new ones.
|
Spain Pharmaceuticals & Healthcare Report |
Was: $1030.00 | |
| Now: $875.00 | ||
| You save: $155.00 (15%) |
Africa |
| Algeria, Egypt, Kenya, Morocco, Nigeria, South Africa and Zimbabwe |
Asia |
| Australia, Bangladesh, China, Hong Kong, India, Indonesia, Japan, Malaysia, Pakistan, Philippines, Singapore, South Korea, Taiwan, Thailand and Vietnam |
Caribbean |
| Puerto Rico |
Europe |
| Belarus, Belgium, Bulgaria, Croatia, Czech Republic, Estonia, France, Germany, Greece, Hungary, Italy, Kazakhstan, Latvia, Lithuania, Moldova, Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Switzerland, Ukraine, United Kingdom and Uzbekistan |
Latin America |
| Argentina, Brazil, Chile, Colombia, Mexico, Peru and Venezuela |
Middle East |
| Bahrain, Iran, Israel, Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi Arabia, Turkey and United Arab Emirates |
North America |
| Canada and United States |
Business Monitor InternationalA Market Leader in Country Risk, Industry Intelligence and Company Research Mermaid House, 2 Puddle Dock, Blackfriars, London EC4V 3DS, UK |
BUSINESS MONITOR INTERNATIONAL's country risk analysis and forecasts, market research on leading industries, and multinational company research is relied upon by corporates, banks, government departments and multilateral organisations in over 125 countries around the world. Country Risk Analysis and Forecasts Industry Intelligence and Market Research Company Research |